 MONT-SAINT-GUIBERT, Belgium, Nov. 02, 2021 GLOBE NEWSWIRE -- Celyad Oncology SA Euronext Nasdaq: CYAD, a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell CAR T therapies for cancer, today announced that the Company plans to participate virtually in the following conference in November 2021: 